Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge Due to FDA Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
Should l Buy AQST?
Source: PRnewswire
- Stock Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application, significantly eroding market confidence in the company's future prospects.
- FDA Deficiency Warning: The FDA indicated that unidentified deficiencies currently hinder discussions regarding the drug's labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026 PDUFA action date.
- Legal Consultation Opportunity: Faruq & Faruqi is investigating potential claims against Aquestive Therapeutics and encourages investors who suffered significant losses to contact them directly, highlighting their commitment to protecting investor rights.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities and influence in the securities law sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.960
Low
6.00
Averages
9.00
High
12.00
Current: 3.960
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anaphylm™ Sublingual Film Clinical Data Released
- Clinical Data Presentation: Aquestive Therapeutics showcased clinical data for Anaphylm™ (dibutepinephrine) sublingual film at the 2026 AAAAI Annual Meeting, highlighting its potential to transform severe allergic reaction management, which could significantly improve patient outcomes.
- Blood Pressure Response Advantage: The study revealed that sublingual administration of Anaphylm did not result in a dip in diastolic blood pressure, a clinically significant finding that enhances understanding of the hemodynamic response to sublingual epinephrine, thereby reducing treatment risks associated with anaphylaxis.
- Product Portability: Anaphylm is designed to be the size of a postage stamp and weighs less than an ounce, making it easy to carry without the need for water or swallowing, which is expected to address both psychological and practical barriers faced by patients in carrying and using epinephrine.
- FDA Approval Prospects: If approved by the FDA, Anaphylm would be the first oral medication for severe allergic reactions, representing a significant innovation in the field and potentially offering patients a more convenient treatment option.
See More
Aquestive Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Aquestive Therapeutics has appointed Matthew Greenhawt as Chief Medical Officer, an internationally recognized expert in allergy and immunology, particularly in food allergies and anaphylaxis, which will enhance the company's medical leadership.
- Transition of Leadership: Greenhawt takes over from Gary Slatko, who served as interim Chief Medical Officer, ensuring continuity and stability in the company's medical strategy during this transition.
- Extensive Experience: Prior to joining Aquestive, Greenhawt was the Chief Medical Officer of the Asthma and Allergy Foundation of America and a Professor of Pediatrics at Children's Hospital Colorado and the University of Colorado School of Medicine, bringing valuable expertise to drive the company's R&D and market strategies.
- Market Reaction: Following the announcement, AQST shares rose by 0.52% in pre-market trading on Nasdaq, reaching $3.90, reflecting positive market expectations regarding the new Chief Medical Officer's potential impact.
See More
Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge
- Stock Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approval prospects.
- FDA Feedback: The FDA indicated that unidentified deficiencies currently hinder discussions on labeling and post-marketing requirements, which not only affects the drug's market outlook but also raises doubts about its approvability ahead of the January 31, 2026 PDUFA action date.
- Legal Consultation Opportunity: Faruqi & Faruqi is investigating potential claims against Aquestive Therapeutics and encourages investors who suffered significant losses to contact partner Josh Wilson directly for legal support to protect their rights.
- Investor Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities in securities law and commitment to safeguarding investor interests.
See More
Faruqi & Faruqi Investigates Investor Losses in Aquestive Therapeutics
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, aiming to provide legal support for investors who have suffered significant losses, highlighting the legal risks the company may face.
- Investor Rights Advocacy: The firm encourages all investors who have incurred losses in Aquestive stock or options to contact partner Josh Wilson directly, demonstrating its commitment to protecting investor rights.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and extensive experience in securities law, which enhances investor trust in its services.
- Contact Information Provided: Faruqi & Faruqi has made direct contact numbers available, ensuring investors can easily access legal consultation, reflecting its commitment to client service.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Aquestive Therapeutics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting concerns for investor rights.
- FDA Notification of Deficiencies: On January 9, 2026, the CEO of Aquestive announced that the FDA identified deficiencies in the NDA for Anaphylm, preventing discussions on labeling and post-marketing commitments, indicating regulatory compliance challenges for the company.
- Significant Stock Price Drop: Following the FDA notification, Aquestive's stock price fell by $2.30, a decline of 37.04%, closing at $3.91 per share, reflecting market concerns regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP, recognized as a premier firm in securities class litigation for over 85 years, focuses on fighting for the rights of victims of securities fraud and corporate misconduct, underscoring the firm's expertise and influence in the legal field.
See More
Faruqi & Faruqi Investigates Aquestive Therapeutics After FDA Concerns
- Stock Price Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application, significantly undermining investor confidence and potentially leading to greater financial strain on the company.
- FDA Deficiency Warning: The FDA indicated that unidentified deficiencies currently hinder discussions regarding labeling and post-marketing requirements, which not only jeopardizes the approval prospects for Anaphylm but may also delay its market launch, further impacting the company's revenue expectations.
- Legal Consultation Opportunity: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, encouraging investors who suffered significant losses to reach out, indicating that the company may face legal liabilities and increasing the legal risks for investors.
- Investor Rights Protection: The law firm has recovered hundreds of millions of dollars for investors since its founding in 1995, demonstrating its expertise in securities law, which may provide legal support for affected investors seeking compensation.
See More
Anaphylm™ Sublingual Film Clinical Data Released
- Clinical Data Presentation: Aquestive Therapeutics showcased clinical data for Anaphylm™ (dibutepinephrine) sublingual film at the 2026 AAAAI Annual Meeting, highlighting its potential to transform severe allergic reaction management, which could significantly improve patient outcomes.
- Blood Pressure Response Advantage: The study revealed that sublingual administration of Anaphylm did not result in a dip in diastolic blood pressure, a clinically significant finding that enhances understanding of the hemodynamic response to sublingual epinephrine, thereby reducing treatment risks associated with anaphylaxis.
- Product Portability: Anaphylm is designed to be the size of a postage stamp and weighs less than an ounce, making it easy to carry without the need for water or swallowing, which is expected to address both psychological and practical barriers faced by patients in carrying and using epinephrine.
- FDA Approval Prospects: If approved by the FDA, Anaphylm would be the first oral medication for severe allergic reactions, representing a significant innovation in the field and potentially offering patients a more convenient treatment option.
See More
Aquestive Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Aquestive Therapeutics has appointed Matthew Greenhawt as Chief Medical Officer, an internationally recognized expert in allergy and immunology, particularly in food allergies and anaphylaxis, which will enhance the company's medical leadership.
- Transition of Leadership: Greenhawt takes over from Gary Slatko, who served as interim Chief Medical Officer, ensuring continuity and stability in the company's medical strategy during this transition.
- Extensive Experience: Prior to joining Aquestive, Greenhawt was the Chief Medical Officer of the Asthma and Allergy Foundation of America and a Professor of Pediatrics at Children's Hospital Colorado and the University of Colorado School of Medicine, bringing valuable expertise to drive the company's R&D and market strategies.
- Market Reaction: Following the announcement, AQST shares rose by 0.52% in pre-market trading on Nasdaq, reaching $3.90, reflecting positive market expectations regarding the new Chief Medical Officer's potential impact.
See More
Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge
- Stock Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approval prospects.
- FDA Feedback: The FDA indicated that unidentified deficiencies currently hinder discussions on labeling and post-marketing requirements, which not only affects the drug's market outlook but also raises doubts about its approvability ahead of the January 31, 2026 PDUFA action date.
- Legal Consultation Opportunity: Faruqi & Faruqi is investigating potential claims against Aquestive Therapeutics and encourages investors who suffered significant losses to contact partner Josh Wilson directly for legal support to protect their rights.
- Investor Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, demonstrating its strong capabilities in securities law and commitment to safeguarding investor interests.
See More
Faruqi & Faruqi Investigates Investor Losses in Aquestive Therapeutics
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, aiming to provide legal support for investors who have suffered significant losses, highlighting the legal risks the company may face.
- Investor Rights Advocacy: The firm encourages all investors who have incurred losses in Aquestive stock or options to contact partner Josh Wilson directly, demonstrating its commitment to protecting investor rights.
- Historical Performance Review: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and extensive experience in securities law, which enhances investor trust in its services.
- Contact Information Provided: Faruqi & Faruqi has made direct contact numbers available, ensuring investors can easily access legal consultation, reflecting its commitment to client service.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Aquestive Therapeutics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting concerns for investor rights.
- FDA Notification of Deficiencies: On January 9, 2026, the CEO of Aquestive announced that the FDA identified deficiencies in the NDA for Anaphylm, preventing discussions on labeling and post-marketing commitments, indicating regulatory compliance challenges for the company.
- Significant Stock Price Drop: Following the FDA notification, Aquestive's stock price fell by $2.30, a decline of 37.04%, closing at $3.91 per share, reflecting market concerns regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP, recognized as a premier firm in securities class litigation for over 85 years, focuses on fighting for the rights of victims of securities fraud and corporate misconduct, underscoring the firm's expertise and influence in the legal field.
See More
Faruqi & Faruqi Investigates Aquestive Therapeutics After FDA Concerns
- Stock Price Plunge: Shares of Aquestive Therapeutics fell approximately 40% intraday on Friday after the FDA identified deficiencies in its New Drug Application, significantly undermining investor confidence and potentially leading to greater financial strain on the company.
- FDA Deficiency Warning: The FDA indicated that unidentified deficiencies currently hinder discussions regarding labeling and post-marketing requirements, which not only jeopardizes the approval prospects for Anaphylm but may also delay its market launch, further impacting the company's revenue expectations.
- Legal Consultation Opportunity: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, encouraging investors who suffered significant losses to reach out, indicating that the company may face legal liabilities and increasing the legal risks for investors.
- Investor Rights Protection: The law firm has recovered hundreds of millions of dollars for investors since its founding in 1995, demonstrating its expertise in securities law, which may provide legal support for affected investors seeking compensation.
See More
